女人的中年:阿尔茨海默氏症预防的前线
Lisa Mosconi1,2
1Departments of Neuroscience, Neurology and Radiology, Weill Cornell Medicine, New York New York, USA.
The Journal of clinical investigation
|March 16, 2026
概括
女性面临更高的阿尔茨海默氏病 (AD) 风险,因为与更年期相关的神经内分泌衰老. 中年期的荷尔蒙变化为针对女性的AD预防策略提供了一个关键的窗口.
科学领域:
- 神经内分泌学神经内分泌学
- 老年学是一门学科.
- 妇女健康 妇女健康
背景情况:
- 阿尔茨海默病 (AD) 对女性的影响不成比例,近三分之二的患者是女性.
- 从历史上看,女性的寿命被引用,但新出现的证据表明女性的性别特异性生物学因素,特别是更年期期间的神经内分泌衰老.
- 更年期过渡 荷尔蒙变化越来越多地被认为是女性可修改的阿尔茨海默病风险因素.
研究的目的:
- 突出中年神经内分泌衰老作为女性患阿尔茨海默病 (AD) 易受伤害的明显窗口.
- 为了强调与更年期相关的未经研究的AD风险因素,包括早期更年期和血管运动症状.
- 倡导AD预防的范式转变,强调性别特定的,时间敏感的策略.
主要方法:
- 本综述综合了有关阿尔茨海默病 (AD) 性差异和神经内分泌衰老作用的现有证据.
- 它检查了与更年期相关的荷尔蒙变化对AD风险的影响.
- 它讨论了更年期荷尔蒙治疗对阿尔茨海默病预防的潜力,并确定了研究缺口.
主要成果:
- 关键的神经内分泌衰老因素,如早期更年期,卵巢切除,血管运动症状和情绪障碍与AD风险增加有关,但仍未得到充分研究.
- 更年期激素治疗显示出预防AD的潜力,特别是卵巢切除术后,但缺乏临床试验.
- 到2050年,全球大量女性将接近更年期,这增加了针对性预防的紧迫性.
结论:
- 中年期的神经内分泌衰老是阿尔茨海默病 (AD) 预防妇女的关键,但被忽视的时期.
- 迫切需要特定于性别的,生物知情的策略来解决与更年期相关的AD风险.
- 将科学见解转化为可扩展的护理对于重新定义老龄化女性人口的AD预防至关重要.
更多相关视频
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
34.1K
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.8K
相关概念视频
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Dementia
660
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
660
Cognitive Development During Adulthood
1.1K
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
1.1K
Menopause
5.1K
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
5.1K
Atherosclerosis III: Management
567
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
567
